METHODS FOR TREATMENT OF POSTOPERATIVE INFLAMMATION WITH REDUCED INTRAOCULAR PRESSURE
Methods of treating a subject after ocular surgery are disclosed. The methods include administering to an eye of a subject in need thereof a composition comprising at least one corticosteroid or an ophthalmically acceptable salt thereof in an ophthalmically acceptable vehicle that can provide a sustained release of the at least one corticosteroid or an ophthalmically acceptable salt thereof. Advantageously, the composition does not result in a statistically significant elevation in intraocular pressure in a statistically significant number of subject eyes when administered twice daily over a period of two weeks.
1 . A method of treating a subject after ocular surgery, the method comprising administering to an eye of a subject in need thereof a composition comprising at least one corticosteroid or an ophthalmically acceptable salt thereof in an ophthalmically acceptable vehicle that can provide a sustained release of the at least one corticosteroid or an ophthalmically acceptable salt thereof, wherein the composition does not result in a statistically significant elevation in intraocular pressure in a statistically significant number of subject eyes when administered twice daily over a period of two weeks.
2 . The method of claim 1 , wherein the composition is administered daily over at least a one week period.
3 . The method of claim 1 , wherein the composition is administered one to four times a day for a period of one to six weeks.
4 . The method of claim 1 , wherein the vehicle comprises an aqueous suspension including a carboxy-containing polymer.
5 . The method of claim 4 , wherein the carboxy-containing polymer is in an amount of about 0.5% to about 1.5% by weight of the composition.
6 . The method of claim 4 , wherein a viscosity of the composition is in the range of about 1,000 to about 2,000 cps.
7 . The method of claim 4 , wherein the at least one corticosteroid or an ophthalmically acceptable salt thereof is in an amount of about 0.01% to about 1% by weight of the composition.
8 . The method of claim 4 , wherein the ocular surgery is among one of the following: cataract surgery, LASIK, or photorefractive surgery.
9 . The method of claim 1 , wherein the vehicle comprises an aqueous suspension including a carboxy-containing polymer and a cationic polymer.
10 . The method of claim 9 , wherein the carboxy-containing polymer is in an amount of about 0.5% to about 1.5% by weight of the composition.
11 . The method of claim 9 , wherein a viscosity of the composition is in the range of about 1,000 to about 2,000 cps.
12 . The method of claim 9 , wherein the at least one corticosteroid or an ophthalmically acceptable salt thereof is in an amount of about 0.01% to about 1% by weight of the composition.
13 . The method of claim 9 , wherein the carboxy-containing polymer is a polycarbophil and the cationic polymer is a chitosan.
14 . A method of treating a patient after ocular surgery, the method comprising administering to an eye of a subject in need thereof a composition comprising dexamethasone or a pharmaceutically acceptable salt thereof in an ophthalmically acceptable vehicle that can provide a sustained release of the dexamethasone or an ophthalmically acceptable salt thereof, wherein the vehicle comprises an aqueous suspension of a carboxy-containing polymer and the composition does not result in a statistically significant elevation in intraocular pressure in a statistically significant number of subject eyes when administered twice daily over a period of two weeks.
15 . The method of claim 14 , wherein the vehicle further comprises and a cationic polymer.
16 . The method of claim 15 , wherein the carboxy-containing polymer is a polycarbophil and the cationic polymer is a chitosan.
17 . The method of claim 14 , comprising treating the subject for inflammation after cataract surgery as the ocular surgery.
18 . The method of claim 17 , wherein the carboxy-containing polymer is in an amount of about 0.5% to about 1.5% by weight of the composition.
19 . The method of claim 17 , wherein a viscosity of the composition is in the range of about 1,000 to about 2,000 cps.
20 . The method of claim 17 , wherein the dexamethasone or a pharmaceutically acceptable salt thereof is in an amount of about 0.08% to about 0.15% by weight of the composition.
21 . The method of claim 17 , wherein the composition is administered daily over at least a one week period.
22 . The method of claim 17 , wherein the composition is administered one to four times a day for a period of one to six weeks.
23 . The method of claim 14 , wherein the composition is administered daily over at least a one week period.
24 . The method of claim 14 , wherein the composition is administered one to four times a day for a period of one to six weeks.